Recognizing and correcting failures in glioblastoma treatment
Related Experiment Video
Updated: Apr 30, 2026
Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
Published on: October 27, 2014
Ashish H Shah1, Regina Graham, Amade Bregy
1Department of Neurological Surgery, University of Miami School of Medicine , Miami, Florida , USA.
Abstract:
While current treatment remains universal for glioblastoma, recent evidence has demonstrated marked heterogeneity in their molecular profiles. Due to the near universal rate of recurrence, attention has focused on individualized treatment and subgroup population differences that may influence the efficacy of adjuvant therapy. Recent studies have implicated chemo-radioresistant GBM stem cells (GSCs) in the propagation of heterogeneous tumor profiles. As a result, there has been a shift to classify and target GSCs in order to increase survival and delay relapse. The overall objective of our editorial is to highlight current failures in GBM treatment and to propose novel personalized methods to correct our shortcomings in GBM treatment.
Insights
Glioblastoma (GBM) treatment faces challenges due to tumor heterogeneity and recurrence. Targeting chemo-radioresistant GBM stem cells (GSCs) offers a personalized approach to improve patient survival and delay relapse.
Area of Science:
- Oncology
- Cancer Biology
- Neuroscience
Background:
- Glioblastoma (GBM) exhibits significant molecular heterogeneity despite universal treatment protocols.
- Recurrence is nearly universal, necessitating personalized treatment strategies.
- Chemo-radioresistant Glioblastoma Stem Cells (GSCs) are implicated in tumor heterogeneity and progression.
